Exagen to Announce Fourth Quarter and Year-End 2019 Financial Results on March 25, 2020
March 11, 2020 08:25 ET
|
Exagen, Inc.
SAN DIEGO, March 11, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune...
Exagen to Present at Cowen and Company 40th Annual Healthcare Conference
February 18, 2020 08:25 ET
|
Exagen, Inc.
SAN DIEGO, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune...
Exagen Announces Addition to Russell 3000® and 2000® Indexes
December 16, 2019 08:25 ET
|
Exagen, Inc.
SAN DIEGO, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune...
National Experts in Autoimmunity Tapped to Serve on Exagen’s Scientific Advisory Board
December 10, 2019 08:10 ET
|
Exagen, Inc.
SAN DIEGO, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune...
Equillium Granted U.S. FDA Fast Track Designation for Itolizumab for the Treatment of Lupus Nephritis
December 09, 2019 16:10 ET
|
Equillium
LA JOLLA, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE)
December 03, 2019 07:30 ET
|
Biogen Inc.
The Phase 2 LILAC study met its primary endpoints, demonstrating statistically significant reduction of disease activity in patients with CLE and SLE who received BIIB059 compared to placeboPositive...
Exagen Inc. Announces $26.2 Million Debt Refinancing
November 21, 2019 08:25 ET
|
Exagen, Inc.
SAN DIEGO, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic...
Exagen Inc. to Participate in the 31st Annual Piper Jaffray Healthcare Conference on December 5, 2019
November 20, 2019 05:15 ET
|
Exagen, Inc.
SAN DIEGO, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune...
Equillium to Present at Investor Conferences in November 2019
November 07, 2019 16:07 ET
|
Equillium
LA JOLLA, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium Announces Initiation of the EQUALISE Phase 1b Clinical Trial of Itolizumab for Patients with Lupus Nephritis and Provides Business Update
October 01, 2019 16:05 ET
|
Equillium
Company secures up to $20 million debt facility with Silicon Valley Bank and Oxford Finance LLC Company receives exclusive rights to negotiate licensing rights to develop and commercialize itolizumab...